Compare AMST & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMST | ENVB |
|---|---|---|
| Founded | N/A | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 6.7M |
| IPO Year | 2020 | 2000 |
| Metric | AMST | ENVB |
|---|---|---|
| Price | $0.88 | $1.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 74.7K | ★ 75.1K |
| Earning Date | 10-27-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.83 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $364,777.00 | ★ $39,914,675.00 |
| Revenue This Year | $19,089.81 | N/A |
| Revenue Next Year | $22.86 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 230.24 | N/A |
| 52 Week Low | $0.77 | $1.17 |
| 52 Week High | $3.90 | $795.00 |
| Indicator | AMST | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 37.17 | 41.25 |
| Support Level | $0.77 | $1.17 |
| Resistance Level | $1.11 | $1.53 |
| Average True Range (ATR) | 0.04 | 0.09 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 25.56 | 28.26 |
Amesite Inc is a technology company focused on building and commercializing AI (artificial intelligence)-powered solutions for the enterprise and for professionals, with particular emphasis on the post-acute healthcare market. It operates through two product lines: NurseMagic and LynkMagic. NurseMagic solutions include a B2B (business-to-business) enterprise application and a B2C (business-to-consumer) solution for individual healthcare professionals. LynkMagic provides enterprise AI solutions for healthcare and related organizations. Its products support documentation, workflow, compliance, oversight, and are designed to improve operational quality and efficiency. It has one single operating and reporting segment, B2C and B2B AI-driven solutions.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.